Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Expenses: 2016-2025

Historic Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $11.4 million.

  • Rocket Pharmaceuticals' Accumulated Expenses rose 10.79% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 10.79%. This contributed to the annual value of $11.9 million for FY2024, which is 20.28% up from last year.
  • Rocket Pharmaceuticals' Accumulated Expenses amounted to $11.4 million in Q3 2025, which was up 42.03% from $8.0 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Accumulated Expenses' 5-year high stood at $11.9 million during Q4 2024, with a 5-year trough of $1.6 million in Q1 2022.
  • Moreover, its 3-year median value for Accumulated Expenses was $8.0 million (2025), whereas its average is $8.1 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Accumulated Expenses plummeted by 73.57% in 2022, and later spiked by 156.82% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $4.5 million in 2021, then soared by 120.74% to $10.0 million in 2022, then declined by 0.76% to $9.9 million in 2023, then rose by 20.28% to $11.9 million in 2024, then rose by 10.79% to $11.4 million in 2025.
  • Its Accumulated Expenses stands at $11.4 million for Q3 2025, versus $8.0 million for Q2 2025 and $7.1 million for Q1 2025.